Pediatrix Medical Group, Inc. (MD)
(Delayed Data from NYSE)
$7.31 USD
-0.05 (-0.68%)
Updated May 31, 2024 04:00 PM ET
After-Market: $7.30 -0.01 (-0.14%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.31 USD
-0.05 (-0.68%)
Updated May 31, 2024 04:00 PM ET
After-Market: $7.30 -0.01 (-0.14%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum B VGM
Zacks News
What's in Store for Molina Healthcare (MOH) Q3 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) third-quarter results are likely to be affected by soft revenues, partly offset by improved marketplace business.
What to Expect for WellCare Health's (WCG) Earnings in Q3
by Zacks Equity Research
WellCare Health's (WCG) Q3 results are likely to reflect increased revenues and higher membership, partly offset by elevated expenses.
Teladoc (TDOC) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Teladoc (TDOC) Q3 earning are likely to have benefited from increased membership and visits, and accretive effect of earlier acquisitions.
Mednax (MD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Mednax (MD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HCA Healthcare (HCA) to Post Q3 Earnings: What to Expect
by Zacks Equity Research
HCA Healthcare's (HCA) third-quarter results are likely to reflect elevated expenses, partly offset by higher topline from increase in admissions and licensed beds.
Anthem's (ANTM) Q3 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Anthem's (ANTM) third-quarter earnings gain from increased revenues.
Centene's (CNC) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Centene's (CNC) third-quarter earnings gain traction from higher revenues.
What to Expect for Universal Health's (UHS) Q3 Earnings
by Zacks Equity Research
Universal Health (UHS) is likely to have benefited from strong segmental performances at Acute Care and Behavioral Health in Q3, partly offset by high costs.
Anthem (ANTM) Gears Up for Q3 Earnings: What's in Store?
by Zacks Equity Research
Anthem (ANTM) is likely to have gained from solid revenues in the third quarter.
What's in the Cards for Centene's (CNC) Earnings in Q3?
by Zacks Equity Research
Centene's (CNC) third-quarter earnings are likely to have grown on the back of solid revenues.
MEDNAX (MD) to Sell MedData for Focusing on Core Business
by Zacks Equity Research
MEDNAX (MD) to divest its billing services business for streamlining its operations.
MEDNAX Teams Up With CENTA to Expand Services in Florida
by Zacks Equity Research
MEDNAX (MD) inks a partnership deal with CENTA to strengthen its profile of varied healthcare solutions in Florida.
Mednax Collaborates With Northern Indiana Neonatal Associates
by Zacks Equity Research
Mednax (MD) joins forces with Northern Indiana Neonatal Associates in Fort Wayne to enhance its neonatal services.
Mednax (MD) Down 5.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Mednax (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is MEDNAX (MD) a Profitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if MEDNAX (MD) stock is a good choice for value-oriented investors right now from multiple angles.
MEDNAX's (MD) Earnings Beat Estimates in Q2, Decrease Y/Y
by Zacks Equity Research
Mednax's (MD) Q2 gains on revenue growth, partly offset by rise in expenses.
Mednax (MD) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Mednax (MD) delivered earnings and revenue surprises of 2.30% and 0.07%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat in Store for Molina Healthcare (MOH) Q2 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter earnings are likely to be cushioned by its strategic divestitures as well as cost-reduction plans, partly offset by lower revenues.
Is a Beat in the Cards for Humana's (HUM) Earnings in Q2?
by Zacks Equity Research
Humana's (HUM) second-quarter earnings are likely to gain traction from a solid revenue stream.
What's in the Cards for HCA Healthcare's (HCA) Q2 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) Q2 earnings are likely to be aided by higher admissions and revenues, partly offset by escalating expenses.
WellCare Health's (WCG) Q2 Earnings: What's in Store?
by Zacks Equity Research
WellCare Health's (WCG) Q2 earnings are likely to be supported by higher membership.
Mednax (MD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Mednax (MD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MEDNAX Forges Alliance for Better Health Services in Texas
by Zacks Equity Research
MEDNAX (MD) collaborates with Alfredo Gei MD, P.A. to provide patients with better healthcare services in Houston.
Why Is Mednax (MD) Down 12.3% Since Last Earnings Report?
by Zacks Equity Research
Mednax (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MEDNAX (MD) Q1 Earnings Miss Estimates, Decline Y/Y
by Zacks Equity Research
MEDNAX's (MD) first-quarter earnings disappoint with weak revenues and elevated expenses.